Skip to main content
Signal8

Liminatus Pharma, Inc. (LIMN) Form 8-K — May 27, 2026

$LIMNForm 8-KItems 3.01, 9.01Filed May 27, 2026, 4:30 PM ET0001104659-26-066974Original filing

Liminatus Pharma, Inc. (LIMN) received a notice from Nasdaq confirming it failed to regain compliance with market value listing standards, triggering a delisting process. The company did not meet the $50 million Market Value of Listed Securities or the $15 million Market Value of Publicly Held Shares requirements by the May 18, 2026 deadline. Trading of the company’s common stock and warrants would have been suspended on May 29, 2026, had the company not filed an appeal.

Key figures

Mvls requirement
$50,000,000
Mvphs requirement
$15,000,000
Compliance deadline
May 18, 2026
Suspension date if no appeal
May 29, 2026

Price after filing

1 day: 0.0%7 days: -15.7%30 days: -45.0%

Close on the filing date to close N calendar days later (from $0.18). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Liminatus Pharma, Inc. (LIMN) Form 8-K — May 27, 2026: AI Analysis | Signal8